VAERS Explorer
Back to explore

Report #2825267

Received Feb 7, 2025

Office visit
A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
32 yrs
State
TX
Recovered
Not recovered
Vaccinated
Nov 16, 2024
Onset
Nov 17, 2024
Days to onset
1
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
FLU3INFLUENZA (SEASONAL) (AFLURIA)SEQIRUS, INC.N/AAW1664AIM / RA

Symptoms (4)

ArthralgiaLimb injuryProduct administered at inappropriate siteX-ray limb

Symptom narrative

1. Injury of right shoulder Received influenza vaccine on November 16, 2024 at clinic. Since then, pt developed chronic right shoulder pain. Denied any skin changes. Otherwise, denies any previous shoulder injury/procedures. Exam today otherwise, unremarkable. No TTP around injection site. No skin changes. Pt does recall an unusual higher injection site. - will obtain right shoulder plain film to r/o any bony abnormality - referral sent to physical therapy for evaluation - clinical presentation suggestive of SIRVA (shoulder injury related to vaccine administration), which is not a contraindication for receiving flu vaccine, rather the medical staff may have given the vaccine at the subdeltoid bursa - f/u with me in February 2025 for re-assessment - return precautions provided Ordered: Referral Request 2.0 -

Current illness

None

Medical history

Hip pain History of nephrolithiasis Hyperlipoproteinemia Knee pain Menorrhagia Pain in right arm Right flank pain

Other medications

None

Allergies

No known allergies

Lab data

Shoulder X Ray 4 views 12/19/24 Hi, Your shoulder x-ray came back unremarkable. I did read some literature regarding SIRVA and potentially the administration of the injection was around your subdeltoid bursa, which may cause that pain. Primary management is ibuprofen and physical therapy. If it doesn't improve, please follow-up.